Clinical trial NCT02223208: Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas
Official title: Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Peripheral T-cell Lymphomas (PTCL)
PTCL-NOS
Angioimmunoblastic T-cell Lymphoma (AITL)
ALK- Anaplastic Large Cell Lymphoma (ALCL)
Nodal Peripheral T-Cell Lymphoma of T Follicular Helper Cell Origin
Keywords: PTCL
PTCL-NOS
AITL
ALCL
Lead sponsor: Fondazione Italiana Linfomi - ETS
Sponsor class: OTHER
First posted: 2014-08-22
Enrollment: 89
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a multicenter study that includes two phases:

1. A phase I study to define the maximum tolerated dose (MTD) of Romidepsin in addition to CHOEP-21 and to test the safety and feasibility of CHOEP-21 in combination with dose escalation of Romidepsin (8, 10, 12, 14 mg). The dose level defined as MTD of Romidepsin will be used for the subsequent phase II study.
2. A phase II study to evaluate the efficacy (response rate, progression free survival and overall survival) and safety of Ro-CHOEP-21 incorporated into a treatment strategy including SCT.

Detailed description: PHASE I A1) Induction phase Ro-CHOEP-21 x 3 cycles

* Romidepsin (dose escalation) starting dose: 12mg/ms iv day +1 and +8. Dose modification according to toxicity (14mg/ms day +1 and +8; 10mg/ms day +1 and +8; 8mg/ms day +1 and +8);
* CHOEP-21 (Doxorubicin 50 mg/ms iv day +1; Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1; Cyclophosphamide 750 mg/ms iv day +1; Etoposide 100mg/ms iv from day +1 to +3; Prednisone100 mg orally from days +1 to +5).

According to the response achieved after the first 3 Ro-CHOEP-21 cycles:

* PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by phase A2
* SD or PD: Treatment failures, proceed to salvage according to each institutional policy.

A2) Stem cell mobilization and transplantation phase Response evaluation and one DHAP course followed by peripheral stem cell harvesting.

According to response achieved after 6 Ro-CHOEP-21 cycles:

CR: BEAM or FEAM or CEAM followed by auto-SCT PR

* Allogeneic SCT with HLA-identical (A, B, C, DR, DQ loci) or one antigen mismatched (class I) sibling donors. Donor selection is based on molecular high-resolution typing (4 digits) of the HLA gene loci class I (HLA-A, B, and C) and class II (DRB1, DQB1). In case, no class I and class II completely identical urelated donor (10 out of 10 gene loci) can be identified, the degree of histocompatibility between patient and donor must fulfill with the minimal degree of matching established by the Italian Bone Marrow Donor Registry: HLA-A and HLA-B antigen histocompatibility and HLA-DRB1 allelic histocompatibility.
* when a suitable donor is not available: BEAM or FEAM or CEAM followed by Auto-SCT.
* Haploidentical transplantation is allowed in selected cases \< PR: Treatment failures, proceed to salvage according to each institutional policy.

PHASE II A1) Induction phase Ro-CHOEP-21 x 3 cycles

* Romidepsin dose according to phase I iv day +1 and +8
* Doxorubicin 50 mg/ms iv day +1,
* Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1,
* Cyclophosphamide 750 mg/ms iv day +1,
* Etoposide 100mg/ms iv from day +1 to +3
* Prednisone100 mg orally from days +1 to +5

According to the response achieved after the first 3 Ro-CHOEP-21 cycles:

* PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by phase A2
* SD or PD: Treatment failures, proceed to salvage according to each institutional policy.

A2) Stem cell mobilization and transplantation phase Response evaluation and one DHAP course followed by peripheral stem cell harvesting.

According to response achieved after 6 Ro-CHOEP-21 cycles:

CR: BEAM or FEAM or CEAM followed by auto-SCT PR

* Allogeneic SCT with HLA-identical (A, B, C, DR, DQ loci) or one antigen mismatched (class I) sibling donors. Donor selection is based on molecular high-resolution typing (4 digits) of the HLA gene loci class I (HLA-A, B, and C) and class II (DRB1, DQB1). In case, no class I and class II completely identical urelated donor (10 out of 10 gene loci) can be identified, the degree of histocompatibility between patient and donor must fulfill with the minimal degree of matching established by the Italian Bone Marrow Donor Registry: HLA-A and HLA-B antigen histocompatibility and HLA-DRB1 allelic histocompatibility.
* when a suitable donor is not available: BEAM or FEAM or CEAM followed by Auto-SCT.
* Haploidentical transplantation is allowed in selected cases \< PR: Treatment failures, proceed to salvage according to each institutional policy.

Eligibility criteria: Inclusion Criteria:

1. Age ≥18 e ≤ 65 years
2. Peripheral T-cell lymphomas at diagnosis including: PTCL-NOS, AITL including other nodal TFH, ALK-ALCL
3. Stage II-IV
4. Written informed consent
5. No prior treatment for lymphoma
6. No Central Nervous System (CNS) disease (meningeal and/or brain involvement by lymphoma)
7. HIV negativity
8. Absence of active hepatitis C virus (HCV) infection
9. HBV negativity or patients with HBcAb +, HBsAg -, HBs Ab+/- with HBV-DNA negativity (in these patients Lamivudine prophylaxis is mandatory)
10. Levels of serum bilirubin, alkaline phosphatase and transaminases \< 2 the upper normal limit, if not disease related
11. No psychiatric illness that precludes understanding concepts of the trial or signing informed consent
12. Ejection fraction \> 50% and myocardial stroke in the last year nor QT prolongation (QTc interval \< 480 msec using the Fridericia formula)
13. Clearance of creatinine \> 60 ml/min if not disease related
14. Spirometry Diffusion Capacity (DLCO) \> 50%
15. Absence of active, uncontrolled infection
16. For males and females of child-bearing potential, agreement upon the use of effective contraceptive methods prior to study entry, for the duration of study participation and in the following 90 days after discontinuation of study treatment
17. Availability of histological material for central review and pathobiological studies.

Exclusion Criteria:

1. Age \<18 e \> 65 years
2. Hystology other than: PTCL-NOS, AITL, ALK-ALCL
3. Stage I
4. Prior treatment for lymphoma
5. Positive serologic markers for human immunodeficiency virus (HIV)
6. Active hepatitis B virus (HBV) infection
7. Active hepatitis C virus (HCV) infection
8. Levels of serum bilirubin, alkaline phosphatase and transaminases \> 2 the upper normal limit, if not disease related
9. Ejection fraction \< 50% and no myocardial stroke in the last year or QT prolongation (QTc interval \> 480 msec using the Fridericia formula)
10. Clearance of creatinine \< 60 ml/min if not disease related
11. Spirometry Diffusion Capacity (DLCO) \< 50%
12. Pregnancy or lactation
13. Patient not agreeing to take adequate contraceptive measures during the study
14. Psychiatric disease that precludes understanding concepts of the trial or signing informed consent
15. Any active, uncontrolled infection
16. Prior history of malignancies other than PTCLs in the last five years (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast).

Primary outcomes:
measure: Dose-limiting toxicity (DLT) of Ro-CHOEP-21 (Phase I endpoint)
timeFrame: 3 months
measure: Progression Free Survival (PFS) of Ro-CHOEP-21 (Phase II endpoint)
timeFrame: 18 months
Secondary outcomes:
measure: Proportion of patients reaching SCT (Phase I endpoint)
timeFrame: 6 months
measure: ORR = Overall response rate (Phase I endpoint)
timeFrame: 6 months
measure: Overall Response Rate (ORR) and Complete Response (CR)(Phase II endpoint)
timeFrame: 6 months
measure: Event free survival (EFS) (Phase II endpoint)
timeFrame: 18 months
measure: Overall survival (OS) (Phase II endpoint)
timeFrame: 24 months
measure: Progression Free Survival (PFS) and Overall Survival (OS) (Phase II endpoint)
timeFrame: 3 months
measure: Toxicities (Phase II endpoint)
timeFrame: 18 months
measure: Higher toxicities (Phase II endpoint)
timeFrame: 18 months
measure: Treatment-related mortality (TRM) (Phase II Endpoint)
timeFrame: 24 months
measure: Graft-versus-host disease (GVHD) (Phase II endpoint)
timeFrame: 24 months
Other outcomes:
measure: Evaluation of response biomarkers (eg TET2 mutations)
timeFrame: 8 years
Locations:
city: Alessandria
country: Italy
facility: Ospedale SS. Antonio e Biagio e Cesare Arrigo
state: AL
city: Bologna
country: Italy
facility: Policlinico S. Orsola Malpighi
state: BO
city: Brescia
country: Italy
facility: Spedali Civili
state: BS
city: Cagliari
country: Italy
facility: Ospedale Businco
state: CA
city: Cuneo
country: Italy
facility: Azienda Ospedaliera S.Croce e Carle
state: CN
city: Meldola
country: Italy
facility: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Sede di Meldola
state: FC
city: Genova
country: Italy
facility: IRCCS AOU San Martino - Clinica Ematologica
state: GE
city: Genova
country: Italy
facility: IRCCS AOU San Martino - UO Ematologia 1
state: GE
city: Rozzano
country: Italy
facility: Istituto Clinico Humanitas
state: Milano
city: Milano
country: Italy
facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
state: MI
city: Milano
country: Italy
facility: Fondazione IRCCS "Istituto Nazionale dei Tumori"
state: MI
city: Milano
country: Italy
facility: Azienda Ospedaliera Ospedale Niguarda Ca' Granda
state: MI
city: Palermo
country: Italy
facility: AO Ospedali Riuniti Villa Sofia - Cervello (Presidio Cervello)
state: PA
city: Aviano
country: Italy
facility: IRCCS Centro di Riferimento Oncologico (CRO)
state: PN
city: Parma
country: Italy
facility: AOU di Parma
state: PR
city: Pavia
country: Italy
facility: Fondazione IRCCS - Policlinico San Matteo
state: PV
city: Reggio Emilia
country: Italy
facility: IRCCS Arcispedale "Santa Maria Nuova"
state: RE
city: Rimini
country: Italy
facility: Ospedale degli Infermi
state: RN
city: Torino
country: Italy
facility: AO Città della Salute e della Scienza - Ematologia 1U
state: TO
city: Torino
country: Italy
facility: AO Città della Salute e della Scienza - SC Ematologia
state: TO
city: Udine
country: Italy
facility: AOU "Santa Maria della Misericordia"
state: UD
city: Verona
country: Italy
facility: Ospedale Borgo Roma
state: VR
city: Napoli
country: Italy
facility: Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
city: Novara
country: Italy
facility: Ospedale Maggiore della Carità - SCDU Ematologia
city: Perugia
country: Italy
facility: A.O. di Perugia - Santa Maria della Misericordia
city: Piacenza
country: Italy
facility: Ospedale G. Da Saliceto - AUSL di Piacenza
city: Ravenna
country: Italy
facility: UO Ematologia Ospedale S.Maria delle Croci
Study officials:
affiliation: Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
name: Paolo Corradini, Prof
role: PRINCIPAL_INVESTIGATOR
References: